All In Biotech

Drug Trial Radar · NCT01498822

Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy

A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy

Last checked: Nov 19, 2026Latest source record: Aug 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Jun 2011

Primary completion

Jul 2014

Study completion Jul 2014

Sponsor

Lead sponsor
Korea UCB Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment Failure Rate in subjects with newly diagnosed partial onset seizures with or without secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks from the first dose

Conditions

  • Epilepsy

Interventions

  • LevetiracetamDrug

    250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks

  • OxcarbazepineDrug

    150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects With a Treatment FailureTime frame: Week 0 (First Dose) to Week 50

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • 05

    Busan, South Korea

  • 10

    Busan, South Korea

  • 16

    Busan, South Korea

  • 06

    Daejeon, South Korea

  • 18

    Daejeon, South Korea

  • 23

    Gangwon-Do, South Korea

  • 08

    Goyang-si, South Korea

  • 09

    Goyang-si, South Korea

  • 07

    Gwangju, South Korea

  • 22

    Junggu, South Korea

  • 14

    Seongnam-si, South Korea

  • 01

    Seoul, South Korea

  • 02

    Seoul, South Korea

  • 03

    Seoul, South Korea

  • 04

    Seoul, South Korea

  • 11

    Seoul, South Korea

  • 12

    Seoul, South Korea

  • 13

    Seoul, South Korea

  • 15

    Seoul, South Korea

  • 17

    Seoul, South Korea

  • 20

    Seoul, South Korea

  • 21

    Seoul, South Korea

  • 19

    Ulsan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.